InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases. In pulmonology, they are focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease. Pirfenidone, the only medicine approved for IPF anywhere in the world, is approved for marketing by InterMune in the EU as Esbriet® and is currently in a Phase 3 clinical trial to support regulatory registration in the United States. InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases.

OcuNexus Therapeutics, Inc. develops and commercializes therapeutic products for wound care and tissue repair. The firm offers Nexagon, an oligonucleotide that downregulates the gap junction in tissue repair. Its Nexagon also reduces lesion spread, swelling, inflammation, scarring, and time to wound closure in various tissue types, including the eye, skin, spinal cord, nerve, and brain. The company was founded in 2005 by David Lawrence Becker, Colin C. Green and Bradford J. Duft and is headquartered in San Diego, CA.

GemVax & KAEL Co., Ltd. engages in the production of chemical filters and gas scrubbers for semiconductors. It operates through the Pollution Removal and Bio businesses. Its products include carbon filter, coating resin, media, air refresher, mask, drugs and others. The company was founded on March 10, 1998 and is headquartered in Daejeon, South Korea.

Otago Innovation Ltd. engages in research and developments. The firm is a University of Otago company responsible for developing and commercializing the University's intellectual property. The company was founded in 2002 and is headquartered in Dunedin, New Zealand.

PAEAN Biotechnology, Inc. is a company headquartered in Daejeon, the South Korea, that provides biotechnology research and development services. It was founded in 2013 by Gyu-Beom Han, who has been the CEO since the inception date.

Promedior is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of inflammatory and fibrotic diseases Promedior has developed a novel drug discovery platform to regulate the monocyte-derived cell populations that play key roles in fibrotic, inflammatory and autoimmune diseases. By specifically targeting these cells at the site of injury, Promedior is able to treat the source of aberrant immune system responses, promote tissue healing and resolution, and greatly reduce the risk of systemic side effects inherent in current therapeutic approaches. Promedior is developing drugs to address the most severe and difficult-to-treat fibrotic and inflammatory conditions of the eye, lung and kidney such as glaucoma, age-related macular degeneration, diabetic retinopathy and dry eye disease; pulmonary fibrosis, scleroderma and COPD; and acute and chronic nephropathy.

Shanghai Pharmaceuticals Holding Co., Ltd. engages in the research and development, manufacture, distribution, and retail of pharmaceutical products. The company was founded on January 18, 1994 and is headquartered in Shanghai, China.

Guangdong Shengpu Life Technology Co., Ltd., established on 2006-10-27, Business scope includes natural science research and experimental development;Life Engineering Project Development;Health Sciences Program Research,to develop;Technology Promotion of Research Results of Health Science Projects;Health Sciences Program Research Transfer;Research and development of biological products(Does not include licensed operations);Biomedical Technology Research;Biotechnology Development Services;Biotechnology Consulting,communication service;Biotechnology Transfer Services;Research on water treatment equipment,to develop;Technology development and technical services of artificial intelligence algorithm software;AI Hardware Sales;electronic,Communication and Automatic Control Technology Research,to develop;Investment Advisory Services;Energy saving technology development service;Energy-saving technical consultation,communication service;Energy-saving technology transfer service;E-commerce information consultation;Electronic equipment engineering installation service;Special Equipment Sales;high-tech investment,operate(Does not include licensed operations,Projects prohibited by laws and regulations shall not be operated);Commodity wholesale trade(Except for licensed and approved products);Commodity retail trade(Except for licensed and approved products);Internet Merchandise Sales(Except for licensed and approved products);Import and export(Excluding franchised products);Technology Import and Export;

Martin wholesales agricultural equipment. The company is headquartered in La Ciotat, France.

KIM Co., Ltd., part of Tan Entertainment, is a South Korean company located in Changwon. The firm manufactures precision gears and driving devices.

Sichuan Academy of Chinese Medicine Sciences, a subsidiary of Province of Sichuan, is a company headquartered in China that manufactures medicinal chemicals.

Mardil Medical is a medical device company, develops therapies for structural heart diseases. It offers therapies for abnormalities in the shape of the heart muscle or valves. The company provides VenTouch, a targeted ventricular reshaping system that addresses the root cause of functional mitral valve regurgitation. Its VenTouch system is a conforming jacket that surrounds the heart’s pumping chambers and normalizes their shape with anatomy correcting the adjustability feature. Mardil Medical was incorporated in 2001 and is headquartered in Plymouth, Minnesota.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

TOLREMO therapeutics is a developer of small molecules intended to target novel drug resistance pathways in cancer therapy.The company's molecules specifically eradicate those cancer cells that cause drug resistance, enabling physicians to get personalized anti-drug resistance therapies to meaningfully prolong the lives of cancer patients.

The 301 Hospital (Chinese: 三〇一医院) or People's Liberation Army General Hospital (Chinese: 中国人民解放军总医院), which constitutes simultaneously the PLA Postgraduate Medical School (Chinese: 中国人民解放军医学院), located in Beijing, China, is a military hospital directly subsidiary to Logistic Support Department of the Central Military Commission and the largest general hospital under the auspices of the People's Liberation Army. Its mission includes assuring the health of PLA and China's leaders.

Tibet Jinhada Pharmaceutical Co., Ltd., established on 2005-04-08, Business scope includes research and development,Production,Sell ​​Tibetan medicine,Tibetan medicine preparation,cosmetic,Healthy food,medical instruments,Tibetan incense,Specialty Food;to plant,farming,processing,Buying and selling Tibetan medicinal materials;Consulting services and technology transfer related to Tibetan medicine.

The First Hospital of Jilin University, a subsidiary of Jilin University, is a Chinese company located in Changchun. The firm owns and operates hospital.